Vancouver, British Columbia – TheNewswire – May 21, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP)(OTC:NSPDF) is pleased to provide the following update regarding preparation for a phase 2 clinical trial treatment for COVID 19. (See news release dated, May 19, 2020) Health Canada has performed an initial review of data for a Clinical Trial Application (CTA) and have advised that the Biologic Division within the Health Canada Office of Regulatory Affairs Biologicand Radiopharmaceutical Drugs Directorate is the appropriate channel to which the completed CTA can continue its processing. This significant designation creates a clear path for the CTA to proceed.